Cipla EU to invest an additional € 3 million in Ethris

Cipla had earlier invested € 15 million in Ethris in 2022

USFDA completes audit of contract manufacturing facility of Jubilant Pharmova Montreal unit

The USFDA has issued 15 observations pursuant to the completion of audit. JHSGP will submit an action plan on the observations

Pfizer reports positive results from Echelon-3 study

Detailed data from Phase 3 ECHELON-3 study demonstrate investigational ADCETRIS regimen reduced risk of death by 37 percent compared to chemotherapy alone

Indian medical device industry to touch US$ 50 billion by 2030

India's healthcare sector anticipates telemedicine reaching US$ 5.4 billion by 2025, with AI growing at 45% by 2024 and Healthtech jobs increasing 15-20%

Lupin and Fuji sign agreement for commercialization of Nextstellis in Vietnam and Philippines

Jubilant Draximage to invest US$ 50 million to expand its PET radiopharmacy network

Jubilant's Radiopharma Business to expand positron emission tomography radiopharmacy network

Sun Pharma and Moebius Medical present Phase 2b study on MM-II

There is an urgent need for more therapeutic treatment options for patients with painful osteoarthritis

Health Minister Nadda aims to attain targeted Health goals in the first 100 days of formation of new government

Nadda expressed his concern about growing incidence of Non-Communicable Diseases and the importance of awareness regarding healthy diet and lifestyle

Moderna announces positive Phase 3 efficacy data for next generation COVID-19 vaccine

Higher efficacy was observed in mRNA-1283 compared to Spikevax in adults 18 years of age and older

Kardium announces US$ 104 million in new financing for innovative Atrial Fibrillation Treatment

Private financing round supported by Fidelity Management & Research Company, T. Rowe Price and Durable Capital Partners